Genentech's Obinutuzumab (GA101) Delayed Disease Progression Longer ... Wall Street Journal ... monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan(R) (rituximab ... |
